Extremely high concentration of mexotrexate in blood serum leading to development of acute renal failure in a patient with acute lymphoblastic leukemia after high-dose consolidation

Abstract

Acute renal failure (ARF) is one of rare and severe methotrexate(MT)-induced complications in patients with acute lymphoblastic leukemia. A case of MT-induced renal dysfunction with an extremely high serum MT concentration is reported. This toxicity required conduction of hemodiafiltration for extracorporeal MT elimination. The presence of homozygous mutation of methylene-tetrahydrofolate reductase reflects an individual metabolism of MT and its renal clearance.

About the authors

Mariya Anatol'evna Pimenova

Email: maria_pimenova@mail.ru

Andrey Nikolaevich Sokolov

Email: cat@blood.ru

Lyudmila Semenovna Biryukova

Email: birjukova@blood.ru

Elena Nikolaevna Ustinova

Inna Ivanovna Shaforostova

Email: shiil@yandex.ru

Irina Anatol'evna Donskova

Email: irina.donskova99@mail.ru

Rashit Fargatovich Bogdanov

Email: rashit85@mail.ru

Elena Nikolaevna Parovichnikova

Email: elenap@blood.ru

Valeriy Grigor'evich Savchenko

Email: svg@blood.ru

M A Pimenova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

A N Sokolov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

L S Biryukova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E N Ustinova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

I I Shaforostova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

I A Donskova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

R F Bogdanov

Hematological Research Center, Moscow

Hematological Research Center, Moscow

E N Parovichnikova

Hematological Research Center, Moscow

Hematological Research Center, Moscow

V G Savchenko

Hematological Research Center, Moscow

Hematological Research Center, Moscow

References

  1. LaCasce Ann S. MD Therapeutic use of high-dose methotrexate. http:// www.uptodate.com/patients/.
  2. Warrier A. R., Rejiv R., Biswajit D. et al. High-dose methotrexate in the treatment of acute lymphoblastic leukemia: Toxicity profile and comparison of tolerability betwen two dosage schedules. J. Clin. Oncol. 2010; 28 (suppl 15): abstr. 9573.
  3. Widemann B. C., Adamson P. S. et al. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 1(6): 694-703.
  4. Pitman S. W., Frei E. 3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat. Rep. 1977; 61 (4): 695-701.
  5. Flombaum C. D., Meyers P. A. et al. High-dose leucovorin as sole therapy for Methotrexate toxicity. J. Clin. Oncol. 1999; 17(5): 1589.
  6. Wilmanns W., Sauer H., Schalhorn A. et al. Biochemical control of high-dose methotrexate/Leucovorin rescue therapy. Recent Results Cancer Res. 1980; 74: 42-49.
  7. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br. J. Haematol. 2009; 146(5): 489-503.
  8. Relling M. V., Fairclough D., Ayers D. et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 1994; 12: 1667-1672.
  9. Schwartz S., Borner K., Müller K. et al. Glucarpidase (Carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12(11): 1299-1308.
  10. Liu J. X., Chen J. P. Tan W., Lin D. X. Association between mothfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008; 16(3): 488-492.
  11. Chiusolo P., Reddiconto G., Casorelli I. et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol. 2002; 13 (12): 1915-1918.
  12. Паровичникова Е. Н., Давидян Ю. Р., Исаев В. Г. Итоги лечения острых лимфобластных лейкозов взрослых по протоколу ОЛЛ-2005 как основа для новых исследований. Тер. арх. 2009; 7: 6-15.
  13. Fisher M. C., Cronstein B. N. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 2009; 36(3): 539-557.

Copyright (c) 2011 Pimenova M.A., Sokolov A.N., Biryukova L.S., Ustinova E.N., Shaforostova I.I., Donskova I.A., Bogdanov R.F., Parovichnikova E.N., Savchenko V.G., Pimenova M.A., Sokolov A.N., Biryukova L.S., Ustinova E.N., Shaforostova I.I., Donskova I.A., Bogdanov R.F., Parovichnikova E.N., Savchenko V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies